CClinicalTrials.gg
CompletedNCT05473975BEERSUpdated Jun 25, 2025

Search for a Recanalization of the Sylvian Artery Electro-Physiological Biomarker

An observational study in AIS, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
18 Years and older
Sex
All
01

Study summary

Early recanalization is a major prognostic factor in vascular accidents ischemic brain injury (AIC). The acute phase therapies of AIC aim to recanalization by intravenous thrombolysis and/or mechanical thrombectomy. Recanalization is identified immediately during thrombectomy by per-procedural arteriography. For the thrombolysis, only a performed MRI will validate the recanalization. This "proof of concept" study aims to identify an Electro-Encephalographic biomarker (EEG) of the recanalization in real time, the EEG being easy to set up. This biomarker will be sought during recanalization certified by thrombectomy in order to identify the window time for which the biomarker must be sought on the EEG. During this study, the identified EEG biomarker can be used to validate the recanalization during the intravenous thrombolysis in future studies

02

Conditions studied

  • AIS
03

In context

Lead sponsor

Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 311 studies on the registry; 77 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Inclusions 15 patients hospitalized for an ischemic stroke for whom an MRI identified a proximal sylvian artery occlusion, treatable by mechanical thrombectomy.

Inclusion criteria

  • Patient over 18 years old
  • Presenting a cerebral infarction with proximal occlusion of the sylvian artery requiring thrombectomy
  • No objection to participation in the study

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Patient benefiting from legal protection
  • Absence of affiliation to a social protection scheme
  • Recent cranial surgery not allowing the installation of a scalp EEG
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (actual)
Patient registry
No

Interventions

  • ProcedurePlacement of the EGG

    Placement of the EGG before the beginning of the thrombectomy

06

What researchers measure

Primary outcomes

  1. IElectro-Encephalographic (EEG) marker of recanalization

    dentification of an Electro-Encephalographic (EEG) marker of recanalization in patients with cerebral infarction with proximal occlusion of the sylvian artery and recanalized by mechanical thrombectomy

    Time frame: inclusion visit

07

Study locations

1 site
  • Fondation Ophtalmologique A. de Rothschild
    Paris, 75019, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05473975
Lead sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Responsible party
Sponsor
First posted
Jul 26, 2022
Start date
Jan 24, 2023
Primary completion
Jan 23, 2025
Completion
Jan 23, 2025
Last update
Jun 25, 2025

Study contacts

Michael OBADIA
principal investigator · HOPITAL FONDATION Adolphe de ROTHSCHILD

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion